Cisterna Biologics develops high-purity mRNA using its proprietary SPEcific Capture and Cleavage (SPECC) technology, which eliminates product-related impurities that can compromise therapeutic efficacy. The company addresses the challenges of quality, quantity, and cost in mRNA production, enabling more effective applications in gene editing and protein replacement therapies.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current mRNA production methods struggle to eliminate product-related impurities such as double-stranded RNA (dsRNA), long RNA impurities (LRNA), and short truncated RNA (stRNA). These impurities can increase immunogenicity and compromise the efficacy of mRNA in applications like CRISPR gene editing and protein replacement therapies.
Solution
Cisterna Biologics utilizes its proprietary SPEcific Capture and Cleavage (SPECC) technology to produce high-purity mRNA, eliminating product-related impurities without the need for HPLC purification. This advanced platform leverages cutting-edge chemistry and ribozymes to create mRNA molecules of unparalleled purity, addressing the challenges of quality, quantity, cost, and delivery lead time in mRNA production. By providing exceptionally high-quality mRNA, Cisterna Biologics enables more effective applications in gene editing, protein replacement therapies, and other advanced biotechnological solutions employing mRNA.
Target Audience
The primary customers are researchers and companies in the biotechnology and pharmaceutical industries focused on mRNA-based therapeutics, gene editing, and protein replacement therapies.
Features
- SPECC technology: A proprietary process for producing mRNA of unparalleled purity.
- Eliminates product-related impurities: Removes dsRNA, LRNA, and stRNA without HPLC purification.
- Cutting-edge chemistry and ribozymes: Leverages advanced techniques for mRNA molecule creation.
- High-quality mRNA: Ensures increased efficacy and reduced immunogenicity in therapeutic applications.
- dT-purified and SPECC-purified mRNA: Available to qualified customers on a research use only (RUO) basis.